Back to top
more

Kenvue Inc. (KVUE)

(Real Time Quote from BATS)

$21.74 USD

21.74
13,570,771

+0.30 (1.40%)

Updated Aug 7, 2025 12:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth A Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 26% (183 out of 246)

Industry: Consumer Products - Staples

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Kenvue (KVUE) Q3 Earnings Surpass Estimates

by Zacks Equity Research

Kenvue (KVUE) delivered earnings and revenue surprises of 3.70% and 0.56%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Stay Ahead of the Game With Kenvue (KVUE) Q3 Earnings: Wall Street's Insights on Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Kenvue (KVUE), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2024.

Zacks Equity Research

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for NOBL

Kinjel Shah headshot

J&J's Q3 Earnings & Sales Top: Time to Buy, Sell or Hold the Stock?

by Kinjel Shah

JNJ beats third-quarter estimates for both earnings and sales. Those who already own J&J's stock may stay invested.

Zacks Equity Research

Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Equity Research

J&J Beats on Q3 Earnings, Raises Sales View but Cuts EPS Guidance

by Zacks Equity Research

JNJ beats estimates for third-quarter earnings and sales. It lowers earnings expectations for 2024 but raises the sales guidance range.

Zacks Equity Research

Tilray Brands, Inc. (TLRY) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tilray Brands (TLRY) delivered earnings and revenue surprises of 20% and 8.81%, respectively, for the quarter ended August 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Should JNJ Stock Be in Your Portfolio Ahead of Q3 Earnings?

by Zacks Equity Research

JNJ's Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. It remains to be seen if MedTech sales improved.

Zacks Equity Research

Will Kenvue (KVUE) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Kenvue (KVUE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for SPYD

Kinjel Shah headshot

J&J Seeks 3rd Talc-Related Bankruptcy: Time to Sell the Stock?

by Kinjel Shah

We suggest a new investor should avoid buying JNJ's stock now due to uncertainty surrounding its legal battles.

Zacks Equity Research

Should SPDR S&P Dividend ETF (SDY) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SDY

Zacks Equity Research

Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar?

by Zacks Equity Research

Style Box ETF report for SPYD

Zacks Equity Research

Is SPDR S&P Dividend ETF (SDY) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for SDY

Zacks Equity Research

The Zacks Analyst Blog Highlights Johnson & Johnson, Kenvue and Eli Lilly

by Zacks Equity Research

Johnson & Johnson, Kenvue and Eli Lilly are included in this Analyst Blog.

Kinjel Shah headshot

J&J's Stock Up 12.8% in 3 Months: Time to Buy, Sell or Hold?

by Kinjel Shah

We suggest a new investor should avoid buying J&J's stock now due to uncertainty surrounding its legal battles.

Zacks Equity Research

International Flavors (IFF) Q2 Earnings Top on Higher Volumes

by Zacks Equity Research

International Flavors (IFF) reports volume growth in high-single digits in second-quarter 2024. The company expects 2024 sales to be in the range of $11.1-$11.3 billion.

Zacks Equity Research

Compared to Estimates, Kenvue (KVUE) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Kenvue (KVUE) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Zacks Equity Research

Kenvue (KVUE) Q2 Earnings and Revenues Beat Estimates

by Zacks Equity Research

Kenvue (KVUE) delivered earnings and revenue surprises of 14.29% and 1.75%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Kinjel Shah headshot

How Should You Play J&J (JNJ) Stock After Q2 Earnings Beat?

by Kinjel Shah

Though J&J (JNJ) beat estimates for both earnings and sales in the second quarter, a new investor should avoid buying the stock right now due to its legal troubles.

Kinjel Shah headshot

J&J (JNJ) Q2 Earnings & Sales Top, EPS View Cut on M&A Costs

by Kinjel Shah

J&J (JNJ) beats estimates for second-quarter earnings and sales. It lowers earnings expectations for 2024 due to costs related to recent acquisitions.

Kinjel Shah headshot

J&J (JNJ) Stock Before Q2 Earnings: To Buy or Not to Buy?

by Kinjel Shah

J&J's (JNJ) Innovative Medicines unit sales are expected to have been driven by drugs like Darzalex and Stelara. Surgical procedure recovery and new products are likely to have driven MedTech sales.

Kinjel Shah headshot

J&J (JNJ) Trades Below 200 & 50-Day Moving Averages: Buy the Dip?

by Kinjel Shah

A new investor should avoid buying J&J (JNJ) stock right now due to its legal troubles. However, those who already own the stock may stay invested as the company is generating decent sales growth.

Zacks Equity Research

Want Better Returns? Don?t Ignore These 2 Consumer Staples Stocks Set to Beat Earnings

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.